The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype… Lesen Sie weiter auf: FDA Approves Dupixent® for Treatment of Asthma Quelle: Asthma and Allergy Foundation of America Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)